II. Indications
-
Hyperlipidemia
- Statin Intolerant (e.g. Statin-Induced Myopathy)
- Second or third-line adjunct to Statin therapy if LDL not at goal
III. Contraindications
IV. Mechanism
- Class prototype, Bempedoic Acid, inhibits the enzyme ATP-Citrate Lyase
- ATP-Citrate Lyase is an enzyme key to Fatty Acid biosynthesis
- ATP-Citrate Lyase cleaves citrate into oxaloacetate (and acetyl CoA, ADP and orthophosphate)
- Lowers LDL Cholesterol as a Statin adjunct or alternative
- Does NOT effect Triglycerides or HDL
V. Efficacy
- Limited data on longterm cardiovascular outcomes
- Lowers LDL Cholesterol 20%
- NNT 63 for high Cardiovascular Risk patients to prevent 1 cardiovascular event in 3 years
VI. Dosing
VII. Precautions
- Bempedoic Acid (Nexletol) costs $400/month in 2023
VIII. Adverse Effects
IX. Drug Interactions
-
Pravastatin or Simvastatin
- Risk of Statin-Induced Myopathy when used with Bempedoic Acid (Nexletol)
- Limit Simvastatin doses to 20 mg orally daily when using Bempedoic Acid
- Limit Pravastatin doses to 40 mg orally daily when using Bempedoic Acid
X. Resources
- Bempedoic Acid (DailyMed)
- Bempedoic Acid and Ezetimibe (DailyMed)
XI. References
- (2023) Presc Lett 30(4): 19
- Feng (2020) Prog Lipid Res +PMID:31499095 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
nexletol (on 1/1/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
NEXLETOL 180 MG TABLET | $12.27 each | |
nexlizet (on 1/1/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
NEXLIZET 180-10 MG TABLET | $12.30 each |